Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TK216 |
| Synonyms | |
| Therapy Description |
TK216 binds to and inhibits Ets-family transcription factor, which may lead to anti-tumor effects (PMID: 31182435). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TK216 | TK-216|TK 216 | TK216 binds to and inhibits Ets-family transcription factor, which may lead to anti-tumor effects (PMID: 31182435). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03752138 | Phase I | Decitabine + TK216 TK216 | TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia | Withdrawn | 0 | |
| NCT02657005 | Phase I | TK216 | TK216 in Patients With Relapsed or Refractory Ewing Sarcoma | Terminated | USA | 0 |